Navigation Links
AbGenomics International Obtains FDA Agreement on Its Phase 2 Clinical Trial Plans
Date:8/17/2012

LOS ALTOS, Calif., Aug. 17, 2012 /PRNewswire-iReach/ -- AbGenomics International announced today that it has obtained agreement from U.S. Food and Drug Administration (FDA) for its proposed plans for a phase 2 clinical trial of the novel autoimmune therapeutic candidate, AbGn-168H.

(Photo: http://photos.prnewswire.com/prnh/20120817/CG59299)

Our antibody demonstrated a great safety profile in preclinical safety and phase 1 clinical trial studies in both psoriasis patients and healthy volunteers. In SRD phase 1 psoriasis patient study, a clear biological/pharmacological effect consistent with the proposed mechanism of action of AbG's antibody was demonstrated in patients. The current Phase 2 clinical trial of AbGn-168H will be a multicenter, placebo-controlled, double-blind trial. The primary objective of the study is to demonstrate that AbGn-168H provides safe, durable, and remissive therapeutic effect in psoriatic patients. Additional clinical trials for type-I diabetes, Crohn's and other autoimmune diseases are under evaluation.

About AbGenomics (www.abgenomics.com)

AbGenomics is a biopharmaceutical company focused on the discovery and development of novel medicines to treat diseases with unmet medical need and significant market potential. Currently, the company has two therapeutic candidates in clinical trials. Headquartered in San Francisco Bay Area, U.S., AbGenomics has subsidiaries in the Netherlands and in Taiwan. The Company's strategy is to commercialize its novel products in collaboration with major pharmaceutical partners in order to maximize the opportunity for development and marketing of the Company's compounds.

Media Contact: RUTH LI ABGENOMICS INTERNATIONAL INC., 6509889912, ABG@ABGENOMICS.COM

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE AbGenomics International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
3. Latest Findings in Breastfeeding Science Presented at Medelas 7th International Breastfeeding and Lactation Symposium
4. SurgLine International, Inc. Launches A Wholly Owned Operating Subsidiary To Pursue Cost Containment Strategies
5. International Drug & Explosives Detection Company IDenta Corp. Releases Information to OTC markets.
6. Chindex International, Inc. to Report First Quarter 2012 Financial Results
7. VWR International, LLC Signs Agreement to Acquire basan Germany GmbH
8. Pharmaceutics International, Inc. (Pii) Supports University Pharmaceutical Technology Education and Research
9. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
10. Bacterin International Signs Its Third National GPO Contract with Novation
11. SurgLine International, Inc. Chief Executive Officer, Thomas Toland, Exclusive Interview on Stock Traders Talk Radio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... New York , January 23, 2017 ... Non-Invasive Prenatal Testing Market was valued at US$0.53 bn in ... expanding at a strong 17.50% CAGR between 2014 and 2022. The ... Global Industry Analysis, Size, Volume, Share, Growth, Trends and Forecast 2014 ... Non-invasive ...
(Date:1/23/2017)... The global  anxiety disorders and depression treatment market  is ... incidence of depression worldwide is anticipated to drive the market growth in the ... demand for antidepressants in the recent years. Continue ... ... ...
(Date:1/23/2017)... SAN DIEGO , 23. Januar 2017  ResMed ... China ) und 3B Medical ( Winter ... sich auf eine Vereinbarung über die Beilegung aller globalen ... ist der Verkauf ihrer bestehenden Produkte im ... eine einmalige Zahlung an 3B leisten, um das in ...
Breaking Medicine Technology:
(Date:1/23/2017)... ... January 23, 2017 , ... A Northwestern Pennsylvania ... domain address. Alpine Springs Rehabilitation & Recovery Center’s new website can be found ... along with its redesigned and retooled website. The treatment center has also revamped ...
(Date:1/23/2017)... ... 2017 , ... Ultimate Medical Academy today announced the keynote ... March 23-25, 2017 in Tampa, and reminded educators and education leaders to submit ... Dr. Michelle R. Weise, executive director of the Sandbox Collaborative, the R&D arm ...
(Date:1/23/2017)... ... ... and plastic balance boards have been around since at least the 1950s and are a ... first and only balance board to use a patent-pending design featuring high-pressure inflation technology and ... as well as skill-level adjustable for all ages and abilities. The board can be ...
(Date:1/23/2017)... (PRWEB) , ... January 23, 2017 , ... ... the premiere organization in North America for the scientific development, healthcare training and ... Annual Scientific Session, and its 2017 AAT Member Certification Qualification Courses for Technicians, ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... However, choosing the right method is paramount to success. Selecting an inappropriate measurement ... situations where multiple persons use the same equipment. Rare or expensive substances are ...
Breaking Medicine News(10 mins):